See Street Research during your Free Trial
Clear This Search
Mateon Therapeutics director Donald Rogers disclosed in a filing that he had purchased 250,000 shares of company stock at an average price of 40c per share on April 12. The total value of the purchase was $100,000.
Option delistings effective July 24th include CHF Solutions (CHFS), Spark Networks (LOV), Mateon Therapeutics Inc (MATN), Natures Sunshine Products (NATR), Novogen (NVGN), OHA Investment (OHAI), TPLM Stock (TPLM), Vanguard Natural Resources LLC (Units) (VNRSQ), and Yanzhou Coal Mining Co Ltd (ADR) (YZCAY).
Natures Sunshine Products